Letter to the Office of Science Policy, Engagement, Education, and Communications (OSPEEC) at the National Heart, Lung, and Blood Institute (NHLBI) urging the Institute to include the Afib Optimal Treatment Task Force's critical challenge of developing an effective integrated bleeding risk assessment tool as part of the NHLBI's final Strategic Research Priorities.
Letter to the House and Senate Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittees, urging the Subcommitees to prioritize funding for adult immunization related activities at the Department of Health and Human Services (HHS) for FY2017.
The Alliance for Aging Research wrote a letter to the Centers for Disease Control and Prevention (CDC) requesting modifications to the 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain. Specifically, the Alliance recommended the CDC modify the guidelines by:
Including a statement calling for further investment of federal resources into clinical research to assist providers in tailoring long-term opioid use.
Requiring Department of Health and Human Services (HHS) to provide an updated clinical evidence review of the guidelines
Calling on public and private payers to broadly cover the cost of non-pharmacologic interventions for pain sufferers.
Adding more resources to www.cdc.gov on the safe use of non-opioid pain treatment
Removing the non-evidenced based dosage recommendations
Removing the time/specific pill limit for acute pain treatment
The Alliance for Aging Research submitted a letter to the Patient-Centered Outcomes Research Institute (PCORI) suggesting possible research for the Institute to consider, aimed at improving outcomes for people with Alzheimer's disease. The Alliance encouraged the following topics:
Impact of non-pharmacologic interventions for Alzheimer’s disease on patient outcomes, caregiver burden and rates of institutionalization
Evaluation of screening methodologies, for relative ease/uptake and associated optimization across provider groups and settings of care;
Assessment of how Alzheimer’s disease diagnosis and treatment affects management of comorbidities;
Frequency of emergency room visits for Alzheimer’s disease patients and identification of
best practices for potential mitigation;
Comparisons of currently available tools used to assess cognition to identify which is most
effective for specific populations; and
Impact of knowing positive ApoE genotype status on patient, caregiver, and provider
behaviors/outcomes as compared to ApoE negative status.
This is a statement presented by Alliance Vice President of Public Policy Cynthia Bens at the December 18, 2015, stakeholder meeting regarding reauthorization of the Medical Device User Fee Act (MDUFA).
Sign up for our email newsletter, Living Longer & Loving It, for the latest information on scientific research on aging and health.